Priority,Rule
High Priority (Names of Competitor Assets): ,"Adstiladrin (nadofaragene firadenovec), Anktiva (N-803, Nogapendekin alfa inbakicept), Cretostimogene Grenadenorepvec (CG0070), Oncofid-P-B, TLD-1433, Detalimogene Voraplasmid (EG-70), TARA-002, Imfinzi (durvalumab), Tecentriq (atezolizumab), sasanlimab, Keytruda (pembrolizumab), gemcitabine, docetaxel, rescue BCG, UGN-102, UGN-103, Bavencio (avelumab), Padcev (enfortumab vedotin), Trodelvy (sacituzumab govitecan)"
High Priority (trial names),"CORE-001, QUILT3.032, KEYNOTE-676, KEYNOTE-057, BOND-003, ORION-BC, LEGEND, ADVANCED-2, ABLE-22, ALBAN, POTOMAC, CREST, QUILT-2.004, BRIDGE, PATAPSCO, ENVISION, UTOPIA, PIVOT-006, CORE-008, ATLAS, KEYNOTE-992, NIAGARA, VOLGA"
High Priority (patient populations),"High risk NMIBC BCG-unresponsive, intermediate risk NMIBC, MIBC"
High Priority (other key words),"""bladder sparing"""
